Tim Smith

These positive topline findings highlight the investigational TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis.

Bempikibart use led to clinically meaningful SALT improvements among those with alopecia areata in the phase 2a SIGNAL-AA study at 36 weeks.

New phase 2 findings on tralokinumab, from TRAPEDS-1, show favorable results in children 6 - 11 years with atopic dermatitis.

This review highlights some of the most notable stories covered by the HCPLive team within the first half of 2026.

The supplemental New Drug Application for Arcutis’ roflumilast cream 0.05% (Zoryve) is for mild to moderate atopic dermatitis in those down to 3 months.

This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.

This new analysis indirectly compares the clinical efficacy of risankizumab and icotrokinra in adults living with moderate-to-severe plaque psoriasis.

This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.

At the SDPA 2026 Summer Dermatology Conference, Mark Eliason, MD, and Mili Shum, MD, presented a joint session on treating chronic urticaria (CSU).

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

New findings point to remaining gaps in AI diagnostic success for skin lesions compared with experienced clinicians in dermatology.

This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.

These topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with moderate-to-severe atopic dermatitis.

This potential new treatment option shows potential for patients living with obstructive sleep apnea.

Phase 2 LANTIC trial data show corabotase maintained glabellar line improvement in 60.8% of patients at week 24 versus 36.7% for Dysport.

Adults with difficult-to-treat psoriasis due to overweight or obesity saw notable benefits to both with concomitant ixekizumab and tirzepatide.

Patients with atopic dermatitis and prurigo nodules (AD-PN) saw notable itch reduction in 12 weeks after initiating upadacitinib.

Treatment-associated phenotype switching between psoriasis and atopic dermatitis was noted to be reproducible and bidirectional in real-world clinical settings.

Investigators released long-term data on long-term bimekizumab use in psoriasis suggest, demonstrating sustained efficacy through 4 years.

Investigators used the Global Burden of Disease (GBD) 2023 database to summarize skin cancers’ epidemiology, patterns, and projections to 2050.

This large real-world analysis of patients with vitiligo suggests many individuals remain untreated after diagnosis.

Findings suggest potential value in complete blood count (CBC)-derived parameters for assessments of hidradenitis suppurativa (HS) disease activity and severity.

In the ongoing JADE EXTEND trial, long-term treatment with abrocitinib led to sustained skin clearance and other improvements through 112 weeks.

This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.

The International Eczema Council set out to create a set of consensus-based definitions of remission, LDA, and vLDA in atopic dermatitis.

AbbVie submitted an sNDA to the FDA seeking approval of upadacitinib for severe alopecia areata in adults and adolescents.

These Week 16, phase 2a findings from the EVERLAST-A study assessing ORKA-001 highlight the treatment's potential in those with plaque psoriasis.

This supplemental New Drug Application for roflumilast cream (Zoryve) to the FDA was supported by the INTEGUMENT-INFANT open-label study.

There is an antifungal-resistant dermatophyte spreading globally, and experts are urging clinicians to become more aware.

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.